arrow-circle-full-right arrow-circle-full-up arrow-circle-up arrow-down arrow-right calendar calendar-done facebook flickr home linkedin login pin reload search share signin star twitter video video youtube nav star-plus info signout double-arrow arrow-up checked
Healthcare & Life Sciences

FT Latin America Healthcare & Life Sciences Summit

Riding the Next Wave of Industry Transformation

São Paulo |
Speakers include:
 Ricardo Barros

Ricardo Barros

Brazil

Rifat  Atun

Rifat Atun

Harvard University

Carlos Marinelli

Carlos Marinelli

Grupo Fleury

Overview

Despite the challenging economic and political backdrop of recent years, Latin America remains a market of key interest to healthcare and life science investors, with significant opportunities emerging across the healthcare spectrum both in and beyond the established first tier markets of the region. A growing recognition of the role that value based care, digital technologies and consolidation across a still largely fragmented industry can play in managing costs and driving efficiencies are reshaping the healthcare and life sciences sector -with important implications for providers, investors and patients. Yet opportunity may yet be tempered by continuing uncertainty regarding the economy, and the impact of the new US administration for trade and investment in the region. How will the future unfold?

The FT Latin America Healthcare and Life Sciences Summit, which this year takes place in Brazil, the region’s market leader , will provide a timely opportunity to examine and discuss the major trends shaping the public and private healthcare and life sciences industries of the region, as well as the emerging opportunities and challenges for investors.

Visão geral

Apesar do cenário econômico e político desafiador dos últimos anos, a América Latina permanece um mercado de importante interesse para investidores em cuidados de saúde e ciências biológicas, com oportunidades significativas surgindo por todo o espectro de cuidados de saúde, dentro e além dos mercados de primeiro nível estabelecidos na região. Um crescente reconhecimento do papel que cuidado com base em valor, tecnologias digitais e consolidação num setor ainda grandemente fragmentado podem desempenhar na gestão de custos e para impulsionar eficiências está transformando o setor de ciências biológicas e cuidados de saúde - com importantes implicações para provedores, investidores e pacientes. Mesmo assim, a oportunidade ainda pode ser moderada devido à constante incerteza em relação à economia e o impacto da nova administração dos EUA em termos de comércio e investimentos na região. Como será o futuro de cuidados de saúde na região?

Encontro da FT sobre Cuidados de saúde e Ciências biológicas na América Latina, que este ano ocorrerá no Brasil, líder do mercado na região, oferecerá uma oportunidade específica para analisar e discutir as principais tendências que estão moldando os setores de ciências biológicas e cuidados de saúde do setor público e privado da região, bem como visualizar oportunidades e desafios emergentes para investidores.

fallback
fallback Add to my Calendar 11/29/2017 08:00:0011/29/2017 16:35:00trueFT Latin America Healthcare & Life Sciences SummitDespite the challenging economic and political backdrop of recent years, Latin America remains a market of key interest to healthcare and life science investors, with significant opportunities emerging across the healthcare spectrum both in and beyond the established first tier markets of the region. A growing recognition of the role that value based care, digital technologies and consolidation across a still largely fragmented industry can play in managing costs and driving efficiencies are reshaping the healthcare and life sciences sector -with important implications for providers, investors and patients. Yet opportunity may yet be tempered by continuing uncertainty regarding the economy, and the impact of the new US administration for trade and investment in the region. How will the future unfold?The FT Latin America Healthcare and Life Sciences Summit, which this year takes place in Brazil, the region’s market leader , will provide a timely opportunity to examine and discuss the major trends shaping the public and private healthcare and life sciences industries of the region, as well as the emerging opportunities and challenges for investors.Visão geralApesar do cenário econômico e político desafiador dos últimos anos, a América Latina permanece um mercado de importante interesse para investidores em cuidados de saúde e ciências biológicas, com oportunidades significativas surgindo por todo o espectro de cuidados de saúde, dentro e além dos mercados de primeiro nível estabelecidos na região. Um crescente reconhecimento do papel que cuidado com base em valor, tecnologias digitais e consolidação num setor ainda grandemente fragmentado podem desempenhar na gestão de custos e para impulsionar eficiências está transformando o setor de ciências biológicas e cuidados de saúde - com importantes implicações para provedores, investidores e pacientes. Mesmo assim, a oportunidade ainda pode ser moderada devido à constante incerteza em relação à economia e o impacto da nova administração dos EUA em termos de comércio e investimentos na região. Como será o futuro de cuidados de saúde na região?O Encontro da FT sobre Cuidados de saúde e Ciências biológicas na América Latina, que este ano ocorrerá no Brasil, líder do mercado na região, oferecerá uma oportunidade específica para analisar e discutir as principais tendências que estão moldando os setores de ciências biológicas e cuidados de saúde do setor público e privado da região, bem como visualizar oportunidades e desafios emergentes para investidores.FT-Latin-America-Healthcare-&-Life-Sciences-Summita367b0f7b74840e32c59c89b3f0a12f8MM/DD/YYYY

Simultaneous Translations

Simultaneous translations will be provided at the summit. 

fallback

Henrique Sutton de Sousa Neves' presentation

Download now

2017 BCI Survey - LatAm Special Report

Download now

2017 BCI ​Report ​Survey - LatAm Special Report

Download now

Event Photos

See the photos from FT Latin America Healthcare & Life Sciences Summit here

Screen Shot 2017-12-11 at 11.08.39 AM (2)

fallback

Click here to view pictures from the event

See the photos from FT Latin America Healthcare & Life Sciences Summit here

Screen Shot 2017-12-11 at 11.08.39 AM (2)

fallback

Speakers (29)

 Ricardo Barros

Ricardo Barros

Minister of Health
Brazil

Ricardo José Magalhães Barros has held the post of Minister of Health of Brazil since May 12th, 2016. He has over 25 years of experience in public life. At the age of 28 he was elected mayor of Maringá (1989-1993), his hometown, becoming the youngest to take the position in this municipality. He served as a Federal Congressman for five terms (1995-1998, 1999-2002, 2003-2006, 2007-2010 and 2015-2019) and as government leader in Congress in 2002. He has also served as Paraná’s Secretary of Industry, Trade and Mercosur Affairs. In Congress, he conducted work as President and member of several committees, including President of the Parliamentary Front on the Public Medicines Industry. He was the General Budget Rapporteur of the Joint Committee on Planning, Public Budget and Control, in 2016. Mr Barros was also a member of the Infrastructure Council of the Federation of Industries of the State of São Paulo (FIESP), between 2008 to 2010, and President of the National Council of Economic Development Secretaries (Conserdic) between 2011 and 2012. Mr Barros graduated as a Civil Engineer from the State University of Maringá in 1981 and as a Public Policy specialist from the Federal University of Rio de Janeiro (UFRJ) in 2000. Mr Barros is author of the book "With an eye on Brazil’s money - Federal budget, now you can participate”, published in 2007.

Rifat  Atun

Rifat Atun

Professor of Global Health Systems
Harvard University

Rifat Atun is Professor of Global Health Systems at Harvard University. He is the Faculty Lead for the Harvard Ministerial Leadership Program. In 2008-12 he was a member of the Executive Management Team of the Global Fund as the Director of Strategy, Performance and Evaluation.

Professor Atun’s research focuses on health system reform and innovation in global health systems. He has published 300 papers in leading journals, including in the New England Journal of Medicine, the Lancet, Lancet Oncology, Lancet Diabetes and Endocrinology, Lancet Global Health, Science Translational Medicine, Health Affairs, and the Academy of Management Journal.

Professor Atun has worked at the UK DFID’s Health Systems Resource Centre and has acted as a consultant for the World Bank, WHO, and with many governments to design, implement and evaluate health system reforms. He has undertaken assignments for and acted in a consulting or advisory capacity to leading organizations, including Medtronic, Novartis, Merck & Co, MSD, Pfizer and Roche.

Professor Atun has served as a member of the US National Academy of Medicine Standing Committee on Health Systems, PEPFAR Scientific Advisory Board, and the Advisory Boards of WHO Research Centre for Health Development in Japan, and Norwegian Research Council’s Programme for Global Health and Vaccination Research. He is a member of the UK Medical Research Council’s Global Health Group. He is a member of the Longitude Prize Committee, the largest science prize in the world.

Professor Atun studied medicine at University of London as a Commonwealth Scholar and completed his postgraduate medical training in family medicine and public health, and MBA at the University of London and Imperial College London. He is a Fellow of the Royal College of Physicians (UK), a Fellow of the Faculty of Public Health (UK), and a Fellow of the Royal College of General Practitioners (UK).

Carlos Marinelli

Carlos Marinelli

CEO
Grupo Fleury

Carlos Marinelli is CEO of Grupo Fleury. Prior to assuming this role, he occupied prominent positions in the company in the areas of new businesses development, strategy, innovation and sustainability. From 2012, he served as Executive Director with responsibility for, expanding and improving the business model, and enhancing the performance of the brand.  He joined the company in 2005, Before joining Grupo Fleury, Mr Marinelli worked at Unilever, Grupo Promon and Grupo Pão de Açúcar. Mr Marinelli has a Bachelor’s degree and and Master’s degree from Escola de Administração de Empresas de São Paulo da Fundação Getúlio Vargas (EAESP FGV) with extensions from the University of Texas in Austin and ESADE Business School in Barcelona. His educational background also includes executive education at London Business School and INSEAD. 

Jacson   Barros

Jacson Barros

Chief Information Officer
Hospital das Clínicas , Faculty of Medicine, University of São Paolo (FMUSP)

Jacson Barros has 27 years of experience in Healthcare IT, and is currently serving as the Chief Information Officer of the Hospital das Clínicas, Faculty of Medicine, Univwersity of  São Paolo (FMUSP). In June 2016, he became a member of the Technical Chamber of Health Informatics of the Federal Council of Medicine (CFM) and in May 2017 he assumed the Presidency of the Brazilian Association of CIOs in Health. Mr Barros graduated in Electrical Engineering and has a Master’s degree in Medical Sciences from the Department of Preventive Medicine, FMUSP. He is currently attending the post-graduate Strict Sense program by the Department of Medical Informatics, FMUSP.

Lieutenant General (Ret. ) Thomas    Bostick

Lieutenant General (Ret. ) Thomas Bostick

Senior Vice President, Environment Sector
Intrexon

Lieutenant General (Ret) Thomas Bostick currently serves as the Senior Vice President of the Environment Sector at Intrexon, a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet. Prior to his current position, he served as the 53rd Chief of Engineers and Commanding General of the U.S. Army Corps of Engineers, where he was responsible for most of the Nation’s civil works infrastructure and military construction. Lt. Gen. (Ret.) Bostick also served as the Deputy Chief of Staff, G-1, responsible for total Army personnel and manpower; Commanding General, U.S. Army Recruiting Command; and as the Assistant Division Commander-Maneuver, and then Assistant Division Commander-Support of the 1st Cavalry Division. He deployed with the Division in support of Operation Iraqi Freedom before commanding the Army Corps of Engineers Gulf Region Division, where he was responsible for more than $18bn of reconstruction in Iraq. Lt. Gen. (Ret.) Bostick also served as an Associate Professor of Mechanical Engineering at West Point and was a White House Fellow, working as a special assistant to the Secretary of Veterans Affairs. He has been one of the leading advocates in the federal government on resilience and developing a systems approach to watersheds. He has appeared on CNN, FOX News, CBS Evening News, the Daily Show and more. He has spoken extensively on resilience and led the U.S. Army Corps of Engineers in the completion of the North Atlantic Coast Comprehensive Study: Resilient Adaptation to Increasing Risk report to Congress in 2015. Lt. Gen. (Ret.) Bostick  is a 1978 graduate of the U.S. Military Academy and holds Master of Science Degrees in both Civil Engineering and Mechanical Engineering from Stanford University, and a PhD in Systems Engineering from George Washington University. 

Daniel Coriat

Daniel Coriat

Director
Pugatch Consilium

Daniel Coriat is a Director at Pugatch Consilium. He is an attorney with over 25 years of experience in public affairs, healthcare public policy, cross-border litigation, patient advocacy and corporate reputation. He is licensed to practice law in Florida and California, and at the US Patent and Trademark Office. For 8 years, Mr Coriat led the Latin-American Communications and Public Affairs division of Novartis. In this role, he was in charge of preserving the corporate reputation of the company, overseeing legal matters and business practices to mitigate reputational risks and manage government relations and stakeholder relations, including relations with patients and advocacy groups. The position also entailed conducting Foreign Corrupt Practices Act (FCPA) and compliance training through anti-corruption tools and workshops. Mr Coriat was also responsible for crisis management, leading efforts to restore corporate goodwill, and was responsible for all internal and external communications, including social media. In carrying out this role, Mr Coriat forged strategic cooperation agreements with the governments of Brazil and Mexico on disease management programs, the expansion of clinical trial footprint, centers of excellence in pharmacovigilance, and technology transfer. He also led industry-wide efforts, through regional and local trade associations, to promote high ethical business standards across the pharmaceutical sector in Latin America. Notably, Mr Coriat led alliances with patient advocacy groups across Latin America, prompting PatientView to rank Novartis #1 in all corporate reputation indicators in that region during his tenure. Before Novartis, Mr Coriat practiced law as a litigator at Dewey Ballantine and Greenberg Traurig, two leading law firms in the United States. Mr Coriat holds a law degree from Boston University, an MBA from UNC Chapel Hill and IESA, and a Master’s degree  in Intellectual Property from Franklin Pierce Law Center. He is an active member of the Intellectual Property section of the International Bar Association. He has a background is in Mechanical Engineering. 

Enrico de Vettori

Enrico de Vettori

Leader, Life Sciences & Health Care Industry
Deloitte Brazil

Enrico De Vettori is leader of Deloitte´s life sciences and health care industry group in Brazil and member of Deloitte´s Global Health Advisory Group. He has more than 20 years of experience in the Brazilian health Care industry and 14 years of experience providing consulting services to national and multinational companies. His areas of focus are in the development of market growth strategies, value chain optimization, cost reduction and profit improvement, and operational excellence. He is a frequent speaker in Congress and at life sciences and health care events in Brazil. In 2017, he was recognized as one of the “Hundred Most Influential Leaders of Health in Brazil.” He has worked with many of the largest health care organizations, hospitals, payers, pharmaceutical companies, hospital material suppliers, medical devices manufacturers and diagnostic medicine companies in Brazil.

Leandro  Fonseca

Leandro Fonseca

Acting Director-President
​National Regulatory Agency for Private Health Insurance and Plans (ANS)
Michel Freund

Michel Freund

Operating Partner
Bain Capital Private Equity

Michel Freund is an Operating Partner in the Portfolio Group at Bain Capital Private Equity, a leading global private investment firm with approximately $75bn in assets under management. Prior to joining the firm in 2015, he was at CVC Capital Partners where he was a senior member of the Operations Team.  Previously, Mr. Freund served as an Associate Principal at McKinsey & Company where he focused on technology-enabled growth and operational transformations across the FIG, pharma, transport and media industries.  Mr. Freund started his career as a brand manager at L'Oreal Group and raised to Vice President Marketing at online service platform Smarterwork and Vice President Sales and Marketing Americas at software house LocatioNet. Mr Freund graduated magna cum laude with a Master's Degree in Commercial Engineering from Solvay Business School in Brussels and holds an MBA from Harvard Business School.

Marcos  Hume

Marcos Hume

Market Access Director, Brazil
Medtronic

Marcos Hume is a member of Medtronic’s Local Leadership Team based in the copmpany’s São Paulo office. As Market Access Director for Brazil, his priorities are to develop and implement value-based healthcare projects and market access initiatives to support new business models involving multiple stakeholders. Mr Hume has comprehensive experience in the healthcare industry, performing executive and consulting positions in hospitals, health plans, medical devices and technology corporations. Prior to joining Medtronic, he was Principal for Life-Sciences Industry at Korn Ferry International. Earlier in his career, Mr Hume held diverse roles such as, Principal-Director for Projects & Consulting at Philips Healthcare Transformation Services, Director of Health Information Management and Provincial Strategic Initiatives at Alberta Health Services in Canada and Director of Operations in a number of hospitals and health plans. Mr Hume has a BA in Healthcare Management from UNISINOS and holds a Masters of Business Administration from UFRGS School of Business & HEC Paris.

Pedro Ivo Sebba Ramalho

Pedro Ivo Sebba Ramalho

Deputy Director President
Brazilian Health Regulatory Agency (ANVISA)

Pedro Ivo Sebba Ramalho currently holds the position of Deputy Director President of the Brazilian Health Regulatory Agency (ANVISA). His work in Brazil’s Federal Public Administration has mainly focused on issues related to institutional relations, public management, regulation and regulatory process. As a representative of ANVISA, he has participated in councils, committees and commissions of the Civil House, Ministry of Health, Ministry of Development, Industry and Foreign Trade and the Ministry of Science and Technology. He has also served as a guest Professor at the University of Brasilia, the Oswaldo Cruz Foundation and the Federal University of Sao Paulo, specializing in topics relating to regulation and regulatory impact analysis. Mr Sebba is a pharmacist, and a specialist in health surveillance management. He has a Master’s degree in Pharmacology and a PhD in Social Sciences.

Bruno Lagoeiro

Bruno Lagoeiro

Co-Founder and CEO
PEBMED

Bruno Lagoeiro is Co-founder and CEO of PEBMED, the premier Mobile App development company for point of care decisions in Brazil. He is also President of Brazilian Start-up Health Association. He is a trained physician and graduate of Universidade Federal Fluminense (UFF).

Antonio Leitão

Antonio Leitão

Manager
Longevity Institute Mongeral Aegon

Antonio Leitão is a Manager at the Longevity Institute Mongeral Aegon . In this role, he has coordinated the development of the Urban Development for Longevity Index (IDL project) which evaluates Brazilian cities with regards to their readiness for population aging. He is a former ambassador to Aging 2.0 (a leading platform for innovation in products and services targeting elderly and care providers) in São Paulo and a former contributor to Saúde Business (one of the leading content providers on innovation in the Brazilian healthcare sector). Mr Leitão holds both a Bachelor and a MSc degree in Psychology. He also holds a specialist degree in Geriatrics and Gerontology.

Luiz Moraes

Luiz Moraes

Partner and Executive Director
Supera Online

Luiz Carlos de Moraes is a Partner and Executive Director of Supera Online. Supera Online is a digital exercise platform for the brain, based on the Schools Method formulated by Supera in Brazil, and developed in partnership with Scientific Brain Training, a French company with expertise in neuroscience and human development with headquarters in Lyon, Asia and the United States.

Alexandra Moutet

Alexandra Moutet

Global Head of Patient Affairs
UCB

Alexandra Moutet is Global Head of Patient Affairs of UCB. In this role, she provides leadership in patient engagement across the entire medicine lifecycle continuum. Prior to joining UCB, she was Director of Patient Engagement and Care for AbbVie Europe, where she developed and lead patient-focused strategies aimed at improving the patient experience, patient access and promoting integrated care models. Dr Moutet previously held roles within French consultancies, providing strategic support for health and social security reforms for various governments at an international level and designing development plans for health industry and public health organizations.  She also serves as a Counselor for Social Affairs at the French Embassy in Russia.  Earlier, Dr Moutet created and led a medical center in Kiev dedicated to the follow-up of people evacuated from the Chernobyl nuclear power plant disaster area.  The center was among the first to diagnose and cure children of thyroid cancer. Dr Moutet has a degree in Medicine from Paris University, and has a Master’s degree in Medical Sciences.

Livia Cunha

Livia Cunha

Co-Founder and CEO
CUCO Health

Livia Cunha is Co-Founder and CEO of CUCO Health, a multiple award winning digital health start-up with high potential to impact people's health and lives. Growing up as a physician’s daughter inspired her passion and aspiration to take care of people. She is a Business Manager and graduate of Santa Catarina Federal University. She worked at Fundação CERTI developing Innovative Entrepreneurship projects for Technological Parks, Incubators and Start-ups.

Lucas Najún Dubos

Lucas Najún Dubos

HTA & Policy Reimbursement Lead
Roche Argentina

Lucas Najún Dubos is HTA & Policy Reimbursement Lead for Roche Argentina. One key projects he has led within this role is the implementation of a personalized reimbursement model based in the value of an oncology product. Dr Najún has more than 10 years’ experience within the pharmaceutical industry. Over and above the market access field, his experience has related to clinical operations, at Pfizer and more recently at Roche, and Medical Affairs at both Roche Argentina and Roche Latin America. In addition to his business experience, Dr Najún also actively participates in the scientific and academic fields as both member & President Elect for 2017 to 2019 for the Argentinean regional chapter of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR,) and as Professor in Health Economics at the Universidad Católica Argentina. Dr Najún is a trained Medical Doctor, and has an MBA as well as an MSc in Health Economics.

Luis  Natel

Luis Natel

Chief Executive Officer
Oncoclinicas

Luis Natel is CEO of Oncoclínicas Group, a position he has held since June 2016.  He is an accomplished administrator with a solid background in finance, economics and management processes, acquired at renowned training centers such as the Kellogg School of Management, Northwestern University, USA. He also has extensive health market experience, having worked in companies to include URP Medical Diagnostics (incorporated by Fleury Group) and Notre Dame Intermédica Group, among others. Since 1996, he has held senior executive positions in the areas of corporate strategy to include Superintendent Director of the Division of Diagnostic and Preventive Medicine at Hospital Albert Einstein.

José Eduardo Neves

José Eduardo Neves

Head of Medical Affairs for Global Medicines in Emerging Markets (GEM)
Sanofi Genzyme

José Eduardo Neves is Head of Medical Affairs for Global Medicines and Emerging Markets (GEM) at Sanofi Genzyme, a position he had held since January 2017. He joined Sanofi in 2015 as Regional Medical Officer LATAM. At Sanofi he successfully led the LATAM regional team and also managed all LATAM countries’ medical departments. Mr Neves played a vital role in the launch of local and global products, provided strategic advice in support of business initiatives and coordinated scientific activities within the region. Prior to joining Sanofi, Mr Neves was the Medical Director at AbbVie Brazil. Mr Neves has also had an extensive and successful career in AstraZeneca, holding several senior positions including Medical Director for Latin America, based in Miami, and Vice-President, Respiratory, Inflammatory and Auto Immune Disease, Global Medical Affairs, based in London. Mr Neves earned his Medical Degree from the Sâo Paulo University Medical School (FMUSP), with a Residency in Psychiatry at the Institute of Psychiatry – FMUSP. He also holds an Executive MBA from IBMEC, São Paulo.

Andréa Pereira

Andréa Pereira

Business Technology Director, Brazil
Pfizer

Andréa Pereira is currently the Business Technology Director of Pfizer Brazil, where she has been working for over three years. She has more than 25 years of experience in Information Technology, having worked in a number of different roles for both national and multinational companies in Brazil, She has a Technical Certificate in Computer Science and graduated in Business Administration from Fundação Armando Alvares Penteado in São Paulo. She has also a MBA from the São Paulo Business School and specialized in Information Services at Harvard Business School.

Cesar  Rengifo

Cesar Rengifo

SVP & Area Head for Emerging Markets West (Latin America & Brazil)
GlaxoSmithKline

Cesar Rengifo is Senior Vice President and Area Director for GSK’s Pharma business in Latin America & Caribbean, a position he has held since in August 2015. He has worked in the pharmaceutical sector for over 20 years ago, starting his career in GSK in 1996 in Marketing and assuming positions of increasing responsibility within the commercial area, as well as leading interactions with key stakeholders, to include local and regional medical societies, Ministries of Health and PAHO (Pan-American Health Organization) representatives. His many years of experience as a General Manager in various countries to include Colombia, Puerto Rico and Brazil provided experience of operating in complex business environments and healthcare systems, and dealing with challenges ranging from strong FDA patent laws to low price, highly competitive generic markets. In the course of his career, Mr Rengifo has led groundbreaking and multi-stakeholder projects to increase access to innovative products in the region, including efforts to support widespread inclusions in Universal Mass Vaccinations schemes across Latin America with local and regional authorities, and innovative collaboration models with the government in Brazil to transfer technology to Brazil for Vaccines and HIV products with the potential to impact 200 million people. Mr Rengifo also represented Brazil on GSK’s Global Respiratory Franchise Board for two years. Mr Rengifo has always always played an active role in local industry associations, and for and even led seven years served as a Board Member for Interfarma, the Association for research lead pharmaceutical companies in Brazil. Mr Rengifo also represents GSK Emerging Markets regions on PhRMA’s International Section Executive Committee (ISEC), setting the direction and strategy for PhRMA’s International Program.  Mr Rengifo holds a Business Administration (BA) degree from the EAN University; and a Master degree in Marketing from the Los Andes University, Colombia.

Eva Maria  Ruiz de Castilla

Eva Maria Ruiz de Castilla

Regional Director LATAM
Global Alliance for Patient Access (GAfPA)

Eva Maria Ruiz de Castilla is Regional Director, LATAM for the Global Alliance for Patient Access (GAfPA). She is a global leader in patient-based organizational capacity building and has collaborated and developed strong relationships with key patient groups and advocates in several therapeutic areas, including NCDs and rare diseases. She also helped forming multi-sectoral forums and coalitions formed by patient groups, physicians, public health specialists and government officials to generate dialogue and action plans to tackle some of the most important public health issues in the Latin America region such as biologics, patient safety and Health Technology Assessment (HTA).  Ms Ruiz de Castilla has more than 17 years of experience providing strategic communications counsel for global pharmaceutical companies and health organizations. She has provided consulting services to Peruvian ministries of Health, Social Development, Housing, Women, and Water-Sanitation to include assistance with the design and coordination of the country’s public-sector social assistance programs. Prior to this, Ms Ruiz de Castilla was Director General of the Peruvian Ministry of Health’s (MINSA) International Coordination office and, before that, served as MINSA’s Director General of Health Prevention and Promotion. She has in-depth experience working with donor country agencies and multilateral organizations such as the Pan-American Health Organization (WHO), UNASUR, United Nations and the World Bank. Ms Ruiz de Castilla is an industrial Engineer by training and has Master’s degree in Political Science by the Sorbonne University Paris as well as PhD studies in Economic Development by the EHESS Paris. She has authored a number of publications and papers on social development, health, and citizen engagement.

Iyari Sánchez-Díaz

Iyari Sánchez-Díaz

National Manager
ISSSTE Diabetes Program

Since 2008, Iyari Sánchez-Díaz has been leading the National Diabetes program (Manejo Integral de Diabetes por Etapas, “MIDE”) at ISSSTE, Mexico’s public health authority and the second largest provider of medicare, pension and social security serving 13 million Mexican Federal government workers and their families. In the course of her career, Dr Sanchez-Diaz has worked in many different positions in the health sector, specializing in diabetes and chronic diseases. Positions she has held in this capacity have included Director of the Mexican Diabetes College. With her broad experience in the public sector in education and health promotion, she has coordinated strategic health promotion projects at the Universidad Autónoma Metropolitana and has served as medical spokesperson at the Fundación Todos contra la Diabetes A.C. She is a GP with a degree in Medicine from the Universidad Autónoma Metropolitana. She received a Master’s degree in Health Promotion from the Maastricht University and a Master’s degree in Health Services Management from the Organization Iberoamericana de Seguridad Social. In addition, she is a Diabetologist and has professional certification in diabetes education awarded by La Salle University.

Denise Santos

Denise Santos

CEO
BP- Beneficência Portuguesa de São Paulo

Denise Santos is the CEO of BP - Beneficência Portuguesa de São Paulo, one of the most important private health centers in Latin America. She assumed this position in April 2013. She has also served as a member of the Health Governance Committee of the Brazilian Institute of Corporate Governance ((IBCG) since 2013, and has been in charge of the Compliance Committee of the National Association of Private Hospitals (ANAHP) since 2015. Ms Santos is the first woman to run a hospital group in Brazil. She was previously President of Hospital e Maternidade São Luiz from 2008 to 2011 and also served as President of Teleperformance and  Brazil’s BenQ Mobile

 

Ms Santos graduated with a degree in Electrical Engineering from the Faculdade de Engenharia Industrial de São Paulo (FEI).She also holds an MBA from the Business School of São Paulo with an extension at the University of Toronto, as well as an in-company MBA through a partnership with renowned institutions to include as Fundação Getúlio Vargas (FGV), where she also participate as Professor, and Babson College University.

Henrique Sutton de Sousa Neves

Henrique Sutton de Sousa Neves

General Manager
Sociedade Beneficente Israelita Brasileira Albert Einstein (SBIBAE)
Thomaz Srougi

Thomaz Srougi

Founder and CEO
dr.consulta

Thomaz Srougi, is Founder and CEO of dr.consulta, a position he has held since 2011. of dr.consulta is a business based on the principle that people are aging unhealthy. Healthcare is becoming more complex, hard to access and expensive. dr.consulta envisions a different world and is working to build it through population health risk management. Prior to his involvement in healthcare, Mr Srougi invested, managed the turnrround and led the IPO of  Brazil ConstrutoraTenda, a low-income homebuilder in 2007. Mr Srougi holds a Bachelor degree in Business, MBA and MPP degrees from University of Chicago, GMP from Harvard Business School, and is a Kauffman Fellow.

Gonzalo Vecina​ Neto

Gonzalo Vecina​ Neto

​Professor of Public Health
University of Sao Paulo

Gonzalo Vecina Neto is a Professor of Public Health University of São Paulo, a position he has held since 1988.He is a physician specialized in hospital administration and healthcare systems. In addition to his academic work, Professor Vecina has built a distinguished career in both the public and private sectors. He served as the CEO of the Sirio Libanes Hospital until 2015, where he was responsible for leading the institution’s expansion project. He also served for two years as Municipal Health Secretary for São Paulo. From 1999 to 2003, he was President of the National Surveillance Agency (ANVISA). Professor Vecina holds an MSc in Business Administration from the Fundação Getulio Vargas.

Luis Villalba

Luis Villalba

General Director
Latin America Federation of Pharmaceutical Industry (FIFARMA)

Luis Villalba  is Director General of the Latin American Federation of Pharmaceutical Industry (FIFARMA), a position he has held since 2014. Dr Villalba and has over 35 years of experience in the pharmaceutical industry.  He joined Hoffmann-La Roche in 1979 as Medical Director for Venezuela.  He then held several positions of increasing responsibility in Switzerland and Ecuador.  In 1991, he joined Sandoz, prior to it’s acquisition by Novartis, as Assistant Vice President and Head of Marketing for the Global Central Nervous System, Bone and Oncology business franchises in Switzerland, In 1995, he assumed the position of General Manager of Sandoz Pharma in Argentina.  Susequently, following the merger of Ciba-Geigy and Sandoz to form Novartis, Dr Villalba served as Country President of Novartis Argentina, later becoming  Regional Head of Novartis Pharma Latin America and then Corporate President for the region until his retirement from Novartis in 2008.  Following retirement, Dr Villalba spent three years in San Francisco, establishing and leading Celtic Pharma West Coast, the US operation of Celtic Pharma Holdings Advisors LLP. He moved to Chile in 2012, where he has been involved consulting and pro bono activities. Prior to his career in industry, Dr Villalba did five years of academic work at the Central University of Venezuela and the National Institute of  Biomedicine in Caracas (Head of the Clinical Pharmacology Unit), and acted as adviser to the registration authorities and several medical societies. He also did graduate work in Clinical Pharmacology as a research and clinical fellow at the Massachusetts General Hospital and the Pharmacology Department of Harvard Medical School. Dr Villalba gained his degree in Medicine in 1969 from the Central University of Venezuela. He also completed graduate studies in Toronto, where he was a research fellow at the Addiction Research Foundation of Ontario and obtained a Master of Sciences in Pharmacology at the University of Toronto.

Pablo Vega

Pablo Vega

Chief of Cabinet
FONASA

Since 2016, Pablo Vega has served as the Chief of Cabinet at the National Health Fund (Fondo Nacional de Salud, FONASA), employing his extensive experience in program management and providing guidance and management support to the Director and to the executive board.  In this role, he is responsible for managing, implementing, monitoring, evaluating and reporting of the progress of the Institution in achieving its strategic goals, including, in particular,r the strengthening of its technology system.

Dr Vega has many years of experience working in the healthcare sector. He gained two years of international and management level experience as the Director of the Professional Exchange Program and the Liaison Officer for Research and Medical Associations at the International Federation of Medical Student’s Associations. Following this, he gained clinical experience in the public health service in Santiago, working at different levels in low-income settings as a primary care physician, and as an emergency doctor at a major hospital in the capital. Later, he served as a health advisor at the Senate in Chile, representing Parliament at different forums and was engaged for two years in managing the roll- out of one of the largest hospitals in the metropolitan area of Santiago.

Dr Vega graduated in Medicine from the University of Chile and holds a Master of Public Health degree with a minor in Health Economics and Public Policy from the same University.

fallback

Chair and Moderator (3)

David  Crow

David Crow

Senior US Business Correspondent
Financial Times

David Crow is a Senior US Business Correspondent for the Financial Times, covering telecoms, technology, and pharmaceuticals. He is based in New York. He previously worked on the FT's main news desk in London, where he edited the front page of the print edition. Before joining the FT he was Managing Editor of City AM, the London financial newspaper.

Mr Crow has an MA in English Literature from the University of Glasgow.

Joseph Leahy

Joseph Leahy

Brazil Bureau Chief
Financial Times

Joseph Leahy is Brazil Bureau Chief for the Financial Times, based in São Paulo. Previously, he served as the FT’s Mumbai Correspondent, as well as Asia Companies Editor and Hong Kong Correspondent.  Before joining the FT in 2000, Mr Leahy was the Jakarta Bureau Chief for AFX and also worked for the South China Morning Post as a subeditor and then as Indonesia Correspondent.  

In 2009, he won the Journalist of the Year award, the most prestigious prize of the Society of Publishers in Asia, for excellence in his reporting of Indian business and politics. He also won the 2009 Indian Express award for Best Foreign Correspondent covering South Asia. While in Hong Kong in 2006, he jointly won the SOPA award for Excellence in Business Reporting for his coverage of Chinese Oil Company CNOOC’s bid for Unocal of the US. In 2011, he jointly won an honourable mention in SOPA’s multimedia category for a Facebook, video and print project on Mumbai’s migrants, “Living the Dream.”  

Mr Leahy is a graduate of the Royal Melbourne Institute of Technology where he received a BA in Journalism.

Greg Reh

Greg Reh

Global Life Sciences & Health Care Industry Leader
Deloitte

Greg Reh is a Global Life Sciences & Health Care Industry Leader and the Global Life Sciences Sector Leader for Deloitte Touche Tohmatsu Limited (Deloitte). He is also the life sciences sector leader for Deloitte in the United States. He has more than 25 years of experience in the life sciences, process manufacturing, consumer and government sectors. His consulting career has spanned such topics as technology strategy, integration solution development and implementation of emerging and disruptive technology. His clients have included multinational pharmaceutical, biotechnology and chemical manufacturing organizations where he successfully led consulting services in support of regulatory, clinical, commercialization and manufacturing operations.

Prior to his consulting career Greg held positions at a government research lab, where he led teams in the design and development of life support devices; and was a lecturer at the University of Pennsylvania.

Agenda - 29th Nov

  • 8:00am
    Registration and Breakfast
  • 8:30am
    Breakfast Briefing

    AI, Telemedicine and Diabetic Retinopathy: New Frontiers in Innovation in Latin America-Mexico’s Experience

    Diabetic retinopathy is a major cause of blindness, yet some 95% of cases are preventable with early screening and diagnosis. Mexico is a case in point. With a diabetic population set to double in the next 20 years and related health costs set to spiral, the government of Mexico is turning to advanced technologies to include artificial intelligence (AI) to address this critical healthcare issue. How is the government of Mexico tackling the challenge? What is the value proposition and the opportunity for pharma companies, insurers and other healthcare players? What is the potential for further advances into related medical fields such as cardiovascular disease, and for the expansion of such technologies into broader clinical settings to include the retail pharmacy space?

    Iyari Sanchez, National Manager, ISSSTE Diabetes Program

  • 9:00am
    Opening Remarks from the Chair / Comentários de abertura do presidente

    Joseph Leahy, Brazil Bureau Chief, Financial Times

  • 9:05am
    Keynote Opening Address / Discurso programático de abertura

     Ricardo Barros, Minister of Health, Brazil 

  • 9:25am
    Panel: Minding the Gap - The Future of Healthcare and Life Sciences in Latin America

    What are the next big challenges facing the healthcare and life sciences markets of Latin America? Consumerism, patient centricity, digital disruption and the transition from value to volume are just some of the major trends underway across the industry. How will these trends play out in Latin America? How can reforms and  progress to date be consolidated and strengthened against a challenging economic and political backdrop? What  reforms and market liberalizations  are creating opportunities, and which initiatives are fostering innovation in the region? 

    Painel: Atenção à situação - O futuro dos cuidados de saúde na América Latina

    Quais são os próximos grandes desafios que os mercados de cuidados de saúde e ciências biológicas enfrentarão na América Latina? Consumerismo, centricidade no paciente, ruptura digital e a transição de valor para volume são apenas algumas das principais tendências que ocorrem atualmente no setor. Como serão estas tendências na América Latina? Como o progresso, em termos de reformas e esforços até o momento para melhorar a qualidade e a eficiência e para controlar os custos, pode ser consolidado e fortalecido em um cenário econômico e político desafiador, bem como os custos crescentes de tecnologias médicas e medicamentos inovadores revolucionários? Quais são as reformas e liberalizações de mercado que estão criando oportunidades, e as iniciativas para promover a inovação na região?

    Rifat Atun, Professor of Global Health Systems, Harvard University
    Eva Maria Ruiz de Castilla, Regional Director LATAM, Global Alliance for Patient Access (GAfPA)
    Thomaz Srougi,Founder and  CEO, dr.consulta
    Luis Villalba, Director General, Latin America Federation of Pharmaceutical Industry (FIFARMA)

    Moderator: Joseph Leahy, Brazil Bureau Chief, Financial Times

  • 10:15am
    Panel: Consolidation, Competition, and Partnering: How is M&A Reshaping the Health and Life Science Landscape of Latin America

    Latin America continue to be a draw for investors attracted by a growing middle class and aging population, in addition to the region’s burgeoning life sciences and expanding healthcare sectors. What are the emerging trends and strategies in M&A, licensing and partnering the region? What are the drivers, opportunities and the challenges? What will be the impact of the current wave of dealmaking on the structure and dynamics of the industry in Latin America?  

    Painel: Consolidação, concorrência e parcerias: como fusões e aquisições estão redefinindo o cenário de cuidados de saúde e ciências na América Latina?

    A América Latina continua chamando a atenção de investidores atraídos por uma classe média e um envelhecimento populacional cada vez maiores, bem como os setores de ciências biológicas em crescimento e de cuidados de saúde em expansão. Quais são as tendências e estratégias emergentes em fusões, aquisições e parcerias na região -- os fatores determinantes, oportunidades e desafios? Qual será o impacto da onda atual de negociações em relação à estrutura e dinâmica do setor na América Latina? 

    Denise Santos, CEO, BP -Beneficência Portuguesa de São Paulo 
    Carlos Marinelli, CEO, Grupo Fleury
    Luis Natel, CEO, Oncoclínicas Group
    Michel Freund, Operating Partner, Bain Capital Private Equity

    Moderator: Joseph Leahy, Brazil Bureau Chief, Financial Times

  • 11:00am
    Networking Coffee Break / Intervalo para café e troca de ideias
  • 11:20am
    Keynote: Challenges and Perspectives on Brazil's Private Health Insurance Market / Discurso programático

    Leandro Fonseca, Acting Director-President, National Regulatory Insurance and Plans (ANS) 

     

  • 11:40am
    Panel: Next Frontiers in Market Access:Value-Based Care - Redefining Healthcare in Latin America?

    Value-based care (VBC) is still in its infancy in Latin America, but its potential to improve care outcomes and reduce costs is increasingly recognized. What are the opportunities and the barriers to the uptake and development of value-based care  and pricing in Latin America? What are the lessons and best practice from more advanced markets where VBC/VBP is taking hold? How is Health Technology Assessment(HTA) evolving as an access decision tool? What are the current shortcomings, and how can they be addressed? What are the implications for providers, payers and patients, and how will VBC ultimately transform healthcare in the region? 

    Painel: Próximas fronteiras no acesso ao mercado: cuidados com base em valor está redefinindo a assistência de saúde na América Latina? 

    Cuidados com base em valor (VBC) ainda está no início na América Latina, mas seu potencial para melhorar os resultados de cuidados e reduzir os custos está sendo cada vez mais reconhecido. Quais são as oportunidades e as barreiras para aceitação e desenvolvimento de cuidados com base em valor e preços na América Latina? Quais são as lições e melhores práticas de mercados mais avançadas nos quais VBC/VBP estão se consolidando? Como a avaliação da tecnologia de saúde (HTA) está progredindo como uma ferramenta de tomada de decisão de acesso? Quais são as desvantagens atuais e como podem ser abordadas? Quais são as implicações para provedores, pagadores e pacientes, e como VBC transformará, essencialmente, os cuidados de saúde na região? 

    Session Keynote: Henrique Sutton de Sousa Neves, General Manager, Sociedade Beneficente Israelita Brasileira Albert Einstein (SBIBAE)

    Gonazalo Vecina Neto, Professor of Public Health, University of Sâo Paulo
    Lucas Najún Dubos, HTA & Policy Reimbursement Lead, Roche Latin America
    Marcos Hume, Market Access Director, Brazil, Medtronic 

    Moderator: David Crow, US Senior Business Correspondent, Financial Times

  • 12:25pm
    Lunch / Almoço

    Luncheon Keynote: Lieutenant General (Ret.Thomas Bostick, Senior Vice President, Environment Sector, Intrexon

  • 1:45pm
    Panel: Digital Conundrums: Risk, Opportunity and Responsibility in a Hyperconnected Healthcare World

    Digital disruption is taking hold in Latin America healthcare markets with digital innovations proving opportunities to improve affordability, access, and reduced costs whilst also enabling the emergence of new and innovative business models However, with opportunity comes risk and responsibility. Cybercrime is rising rapidly up the agenda of healthcare and life science executives as the number and complexity of cyber-attacks and data breaches increases. Data privacy remains a key concern. What is the potential of digital innovation to transform healthcare and life sciences in the region? What are the strategic risks and the real costs of cyber crime? Will the rise of cyber risk slow down the capture of value from digital initiatives and efforts to collaborate? Will it lead to a  backlash against digitization? What is the key to gaining and maintaining stakeholder trust in a digitized world?

    Enigmas digitais: oportunidade, risco e responsabilidade num mundo de cuidados de saúde hiperconectado

    A ruptura digital está assumindo o controle nos mercados de cuidados de saúde da América Latina, com inovações digitais apresentando oportunidades para melhorar a viabilidade financeira, o acesso e custos reduzidos, enquanto também permite o surgimento de modelos de negócio novos e inovadores. Entretanto, com a oportunidade vem o risco e a responsabilidade. O crime informático está se expandindo rapidamente na agenda de executivos de cuidados de saúde e ciências biológicas, à medida que o número e a complexidade dos ataques informáticos e violações de dados aumentam, e a privacidade dos dados permanece uma preocupação importante. Qual é o potencial da inovação digital de transformar os cuidados de saúde e as ciências biológicas na região? Quais são os riscos estratégicos, os cenários de risco e o custo real dos riscos informáticos para as empresas de ciências biológicas e cuidados de saúde? O aumento do risco informático desacelerará a captura de valor de iniciativas digitais e os esforços para colaborar? Causará uma reação adversa contra a digitalização? O que é essencial para obter e manter a confiança das partes interessadas num mundo digitalizado? 

    Jacson Barros, Chief Information Officer, Hospital das Clinicas, University of  Sâo Paolo
    Bruno Lagoeiro, Co-Founder and CEO, PEBMED
    Andréa Pereira, Business Technology Director, Brazil, Pfizer
    Pablo Vega, Chief of Staff, FONASA

    Moderator: David Crow, US Senior Business CorrespondentFinancial Times

  • 2:30pm
    Panel: Patient Engagement and Patient-Centred Care

    Growing consumerism, the expanding focus on patient outcomes as the industry transitions from volume to value as well as the increasing emphasis on the patient voice in decisions relating to product approvals are necessitating a growing focus amongst healthcare and life science companies on patient engagement and patient-centred care. What are the strategies leading companies are employing and the challenges they are facing? What is the key to gaining and maintaining customer engagement?

    Painel: envolvimento do paciente e cuidado centrado no paciente

    Um crescente consumerismo, expansão do enfoque nos resultados do paciente, à medida que o setor muda de volume para valor, bem comoa crescente ênfase na opinião do paciente em relação a decisões associadas com aprovações de produtos estão precisando de um maior foco -- entre as empresas de ciências biológicas e de cuidados de saúde -- no envolvimento do paciente e no cuidado centrado no paciente. Quais são as estratégias que as principais empresas estão utilizando, e os desafios que estão enfrentando? O que é essencial para obter e manter o envolvimento do cliente?

    José Neves, Head of Medical Affairs for Global Medicines in Emerging Markets (GEM) Sanofi Genzyme
    Livia Cunha, Co-Founder and CEO, CUCO Health
    Alexandra Moutet, Global Head of Patient Affairs, UCB

    Moderator:Greg Reh, Global Life Sciences & Health Care Industry Leader, Deloitte 

  • 3:10pm
    Panel: The Aging Opportunity: Perspectives on a Growth Market in Latin America

    Latin America is the fastest-aging region in the world, with an expected tripling of the region’s senior population by mid-century. A geriatric population suffering from multiple diseases is creating significant opportunities for health and life sciences companies focused on improving the quality and reducing the cost of care through digital and other innovative solutions.

    Cuidados de população idosa e residencial associados: perspectivas sobre um mercado em crescimento na América Latina

    A América Latina é a região com envelhecimento populacional mais rápido no mundo e espera-se que a população idosa na região triplique até meados deste século. Uma população geriátrica que sofre de diversas doenças está criando oportunidades significativas para empresas de cuidados de saúde e ciências biológicas comprometidas a melhorar os resultados e a reduzir o custo das condições através de cuidado residencial, monitoramento remoto de pacientes e outras soluções. Qual é o caso de negócio e retorno sobre o investimento em relação aos investimentos em cuidado residencial e telessaúde? Essencialmente, isto aumentará ou reduzirá os custos do sistema? Causará uma maior fragmentação dos cuidados de saúde? Quais são as expectativas e preferências do consumidor com relação aos cuidados residenciais? 

    Antonio Leitão, Manager, Longevity Institute Mongeral Aegon
    Luiz Moraes, Partner and Executive Director, Supera On-Line

    Moderator: David Crow, Senior US Business Correspondent, Financial Times

  • 3:30pm
    Presentation

    Daniel Coriat, Director, Pugatch Consilium

  • 3:40pm
    Panel: The Business of Healthcare and Life Sciences in Latin America - Investors Forum

    International investors share perspectives on the impact of the current macroeconomic and political environment on healthcare and life science investment in the region: How will the new global wave of protectionist sentiment impact trade and investment in the region? Are the worst of the economic challenges now behind us? From affordability, transparency, IP, the rule of law and beyond, what are the remaining barriers to access and investment? Where are the opportunities in the region emerging?

    O negócio de cuidados de saúde na América Latina - Fórum de investidores

    Investidores internacionais e particulares compartilham perspectivas em relação ao impacto do ambiente macroeconômico e político atual nos investimentos em cuidados de saúde e ciências biológicas na região: Como a nova onda global de sentimento protecionista afetará o comércio e o investimento na região? Os piores desafios econômicos já passaram? Da viabilidade financeira, transparência, PI, estado de direito e além, quais são as barreiras restantes ao acesso e ao investimento? Onde as oportunidades estão surgindo na região?

    Session Keynote: Mr Pedro Ivo Sebba Ramalho, Associate Director, National Health Regulatory Agency (ANVISA)

    Enrico De Vettori, Leader, Life Sciences & Health Care Industry Leader, Deloitte Brazil
    Cesar Rengifo,  SVP & Area Head for Emerging Markets West (Latin America & Brazil), GlaxoSmithKline
    Daniel Coriat, Director, Pugatch Consilium

    Moderator: David Crow, Senior US Business Correspondent, Financial Times

     

  • 4:30pm
    Closing Remarks from the Chair / Comentários de encerramento do presidente

    David Crow, Senior US Business Correspondent, Financial Times

Who Attends?

The FT Latin America Healthcare and Life Sciences Summit will be attended by: CEOs, CFOs, CIOs, Chief Medical Officers, Chief Strategy Officers, Heads of R&D, Emerging Markets/Latin America, Global Public Health, Consumer Health, Government Relations, Pricing, Regulation, Market Access and other senior-level executives in the following sectors:

  • Pharmaceuticals, Biotechnology, Generic and Specialty Pharmaceutical companies
  • Medical Devices and Diagnostics
  • Investments (Fund Managers, Venture Capitalists, Private Equity firms, Investment Bankers, IP Groups)
  • Healthcare Provider and Payers
  • Clinical Research Organizations
  • Healthcare IT and Digital Health (Patient records, data, mobile and telehealth applications, social media)
  • Regulation
fallback

Why Attend?

  • Get the inside track on emerging trends and strategies in M&A, licensing and partnering in Latin America
  • Hear how industry leaders are preparing to counter value destruction from rising cyber security risk
  • Debate the opportunities and barriers and value based care in Latin America
  • Keep up to date with leading edge strategies to gain and maintain patient engagement
  • Meet with peers from across the region’s burgeoning healthcare and life science industry
fallback

Fees

Ticket Type                                                             Fee

Early Bird Ticket (ends 18 August)                    USD500

Standard Summit Ticket                                      USD799

fallback

Presented by (1)

The Financial Times is one of the world’s leading business news organisations, recognised internationally for its authority, integrity and accuracy. In 2016 the FT passed a significant milestone in its digital transformation as digital and services revenues overtook print revenues for the first time. The FT has a combined paid print and digital circulation of more than 910,000 and makes 60% of revenues from its journalism.

With the Support Of (1)

About Life Sciences and Health Care at Deloitte*

Deloitte’s life sciences and health care (LSHC) industry group is composed of over 12,000 professionals in over 90 countries. These professionals understand the complexity of today’s life sciences and health care industry challenges, and provide clients with integrated, comprehensive services that meet their respective needs. In today’s environment, LSHC professionals from across the Deloitte network help companies to evolve in a changing marketplace, pursue new and innovative solutions, and sustain long-term profitability.

For more information, visit www.deloitte.com/lifesciences or email dttlshc@deloitte.com.

*Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited (DTTL), a UK private company limited by guarantee, and its network of member firms, each of which is a legally separate and independent entity.

Sponsor (1)

FIFARMA is the Latin American Federation of Pharmaceutical Industry, a regional organization created in 1962 which represents 13 Research and Development Pharmaceutical Companies and 9 local Trade Associations across the Latin American region.
FIFARMA members are involved in the research and development of innovative healthcare products, and provide state of the art healthcare solutions through a variety of products and services aimed to improve and save patients’ lives across the globe, placing patient safety as one of our main objectives.
In this effort to improve global health, FIFARMA works closely with intergovernmental bodies, nongovernmental organizations, Latin American health authorities and civil society organizations among others.

Luncheon Keynote (1)

About Intrexon Corporation 
Intrexon Corporation (NYSE: XON) is Powering the Bioindustrial Revolution with Better DNA™ to create biologically-based products that improve the quality of life and the health of the planet.  The Company's integrated technology suite provides its partners across diverse markets with industrial-scale design and development of complex biological systems delivering unprecedented control, quality, function, and performance of living cells.  We call our synthetic biology approach Better DNA®, and we invite you to discover more at www.dna.com or follow us on Twitter at @Intrexon, on Facebook, and LinkedIn.

Breakfast Briefing (1)

Where Artificial Intelligence (AI) becomes real. All eyes have a story, we help you read it through Artificial Intelligence. We apply AI technology to save lives on a daily basis.

Our mission is early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence.

Diagnos is a leader in Artificial Intelligence and healthcare technical services including algorithm development, data analysis, and image processing ever since 2001.

We’re currently in 15 countries, having presence 125 screening sites, and +170,000 patients under Diagnos’ care.

Exclusive PR Partner (1)

In Press Porter Novelli is one of the leading agencies in Communications and Public Relations in Brazil. It was founded in 1988, Rio de Janeiro. With offices in Brasília, São Paulo and Rio de Janeiro, as well as partnerships on several other Brazilian capitals, In Press Porter Novelli has more than 300 employees, it has among its clients many of the world's largest businesses and organizations.

Supporting Partners (4)

Brazilian Medical and Dental Devices Manufacturers Association (ABIMO) is the entity that represents the Brazilian health products industry, which promotes the sustainable growth of the sector in the national and international markets.
Founded in 1962, ABIMO was born from the idea of 25 manufacturers of medical and dental products. They decided to come together to strengthen, organize and regulate the segment. At the time, the group kept the focus of working for the national industry and guaranteeing the quality and safety of medical equipment produced in the country.

Fostering impact businesses in life sciences: that is Biominas Brasil specialty.

Biominas Brasil offers solutions to all development stages of a business in the life sciences sector. The company has in its core business initiatives aimed at entrepreneurship and innovation, from the acceleration of ideas to business expansion. It is also a reference in consulting services (project management, elaboration of reports and guides) and in the relationship with national and international life sciences ecosystem (production of high level events, such as the BIO Latin America Conference). These are, therefore, the three business areas of Biominas Brasil: Entrepreneurship & Innovation, Consultancy and Business Relations.

Biominas Brasil was founded in 1990 through the initiative of a group of companies, with the intention of developing the life sciences sector in the State of Minas Gerais. Originally with this purpose, working to stimulate the creation of new companies and supporting the existing ones, the institution expanded its field of expertise and geographic scope along the years. Currently, Biominas Brasil has a large portfolio of services and clients scattered around the country and abroad. With specialized professionals and solutions developed according to client’s specifications, Biominas Brasil is the perfect partner for development of business with focus on life sciences.

The institution stands out in view of its exclusive focus, expertise and large network of domestic and foreign companies, in addition to professionals that provide specialized technical knowledge and market vision.

Founded in 1990, INTERFARMA is a non-profit sectoral entity that represents Brazilian and foreign companies and researchers responsible for health innovation in Brazil.

These agents seek, through innovation, to promote and encourage the development of the scientific and technological research industry in the country focused on the production of pharmaceutical inputs, raw materials, medicines and products for human health.

THE ORGANIZATION’S COMMITMENTS
INTERFARMA primary goals include disseminating the innovation concept as an economic development vector, seeking to create a safe, stable and favorable environment for investments.

Moreover, INTERFARMA promotes the interaction and tightening of relationships among players, mainly health care authorities, in order to discuss matters such as clinical research, regulatory environment, biotechnology, ethics, and the fight against informality, which we understand are key to improve the debate around public health care in the country.

These are our main commitments:
• Take care of the Brazilian patient’s health;
• Disseminate the values of our Code of Conduct and make ethics become an inseparable element of our members and recognized by the society;
• Work toward the exchange and cooperation with other Brazilian and foreign organizations;
• Show society the importance of medical and pharmaceutical research;
• Foster actions of social and environmental responsibility;
• Promote the technical and scientific improvement of our members.

FIFARMA is the Latin American Federation of Pharmaceutical Industry, a regional organization created in 1962 which represents 13 Research and Development Pharmaceutical Companies and 9 local Trade Associations across the Latin American region.
FIFARMA members are involved in the research and development of innovative healthcare products, and provide state of the art healthcare solutions through a variety of products and services aimed to improve and save patients’ lives across the globe, placing patient safety as one of our main objectives.
In this effort to improve global health, FIFARMA works closely with intergovernmental bodies, nongovernmental organizations, Latin American health authorities and civil society organizations among others.

Venue - Hotel Unique

Hotel Unique
Av. Brigadeiro Luís Antônio, 4700 - Jardim Paulista, São Paulo - SP, 01402-002, Brazil
Sao Paulo

Brazil

fallback

Hotel Accommodation

Financial Times has arranged very special rates for Summit attendees at the host hotel​, Hotel Unique​*

Standard / Deluxe - BRL 1200+taxes
Premium - BRL 1416+taxes
Rodeo Drive Suite - BRL 2520+taxes

Please inform the hotel that you are part of the Financial Times group, or use the code A-FINANCIAL

Accommodation queries

For any accommodation queries, please contact:
​Email: reservas@hotelunique.com
​Phone:​ +55 11 3055 4710 ​OR ​toll free on 0800 770 8771.

​*​Rooms are based on availability and rates cannot be guaranteed.

We have also put together a unique Hotel Map that shows hotel deals close to the event venue. To view, click here

fallback

CONTACT US

Angela Letinov
Speaking Opportunities
Financial Times
Tim Powell
Sponsorship Opportunities
Financial Times
Funmbi Adenubi
Delegate Booking and Registration Enquiries
Financial Times
Chandni Saberwal
Media Partner & Press Inquiries
Financial Times